Innovative Nipocalimab Trial for HDFN Treatment Powered by BillionToOne
XTalks
DECEMBER 28, 2023
BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. The trial, a randomized, placebo-controlled, double-blind, multicenter study, aims to evaluate nipocalimab as a treatment for severe hemolytic disease of the fetus and newborn (HDFN) in pregnancies at risk.
Let's personalize your content